Please enable JavaScript to continue using this application.

Compare $KRRO vs $RNA | Chartloom

Compare

$KRRO vs $RNA

Korro Bio Inc · Atrium Therapeutics Inc

KRRO

Korro Bio Inc

RNA

Atrium Therapeutics Inc

Compare $KRRO vs $RNA

Comparing Korro Bio Inc and Atrium Therapeutics Inc

KRROKorro Bio Inc

RNAAtrium Therapeutics Inc

KRROKorro Bio Inc

Market cap

$147M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

143.63x

Rev growth (TTM)

-62.1%

YTD performance

26.2%

52W performance

-77.8%

FCF yield

-46.6%

RNAAtrium Therapeutics Inc

Market cap

$144M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

22.0%

YTD performance

-88.3%

52W performance

-82.6%

FCF yield

-55.5%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KRRO

RNA

Detailed metrics comparison

KRRO

Korro Bio Inc

RNA

Atrium Therapeutics Inc

Market Cap

KRRO$147M

RNA$144M

Enterprise Value

KRRO$122M

RNA$71M

Price

KRRO$10.16

RNA$8.40

P/E Ratio

KRRON/A

RNAN/A

P/S Ratio

KRRO61.51x

RNA3.48x

EV/Sales

KRRO51.05x

RNA1.73x

EV/EBITDA

KRRO0.00x

RNA0.00x

P/B Ratio

KRRO1.38x

RNA0.63x

P/FCF Ratio

KRRON/A

RNAN/A

EV/FCF

KRRO-1.78x

RNA-0.89x

PEG Ratio

KRRON/A

RNAN/A

Forward P/E (NTM)

KRRON/A

RNAN/A

Forward P/S (NTM)

KRRO143.63x

RNAN/A

Revenue (TTM)

KRRO$2M

RNA$41M

Revenue Growth (YoY)

KRRO-62.1%

RNA22.0%

Forward Rev Growth

KRRO240.0%

RNA-94.2%

Gross Margin (TTM)

KRRO0.0%

RNA0.0%

Operating Margin (TTM)

KRRO0.0%

RNA0.0%

EBITDA Margin (TTM)

KRRO-3068.6%

RNA-215.0%

Net Margin (TTM)

KRRO-4477.1%

RNA-209.2%

FCF Margin (TTM)

KRRO-2865.9%

RNA-193.4%

Net Income (TTM)

KRRO$-107M

RNA$-86M

FCF (TTM)

KRRO$-68M

RNA$-80M

EPS (TTM)

KRRO-$6.05

RNA-$5.05

ROE (TTM)

KRRO-11426.0%

RNA-4030.0%

ROA (TTM)

KRRO-6857.0%

RNA-5864.0%

ROIC (TTM)

KRRO-11426.0%

RNA-4433.7%

Cash

KRRO$25M

RNA$72M

Debt

KRRO$0

RNA$0

Net Cash/Debt

KRRO$25M

RNA$72M

Current Ratio (TTM)

KRRO9.55x

RNA8.73x

Quick Ratio (TTM)

KRRO9.11x

RNA8.59x

Debt/Equity (TTM)

KRRO0.00x

RNA0.00x

Debt/Assets (TTM)

KRRO0.0%

RNA0.0%

Interest Coverage (TTM)

KRRON/A

RNAN/A

Net Debt/EBITDA (TTM)

KRRO0.00x

RNA0.00x

Beta

KRRO3.27

RNA1.20

52W Performance

KRRO-77.8%

RNA-82.6%

YTD Performance

KRRO26.2%

RNA-88.3%

% from 52W High

KRRO-81.8%

RNA-88.5%

% from 52W Low

KRRO95.2%

RNA10.1%

Asset Turnover (TTM)

KRRO0.04x

RNA0.28x

FCF Yield (TTM)

KRRO-46.6%

RNA-55.5%

Earnings Yield (TTM)

KRRO-72.8%

RNA-60.1%

Dividend Yield (TTM)

KRRON/A

RNAN/A

Rule of 40

KRRO-2,927.9

RNA-171.3

EV/GP/RG

KRRON/A

RNAN/A

Ticker research

View KRRO research View RNA research

Metric	KRRO Korro Bio Inc	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$147M	$144M
Enterprise Value	$122M	$71M
Price	$10.16	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	61.51x	3.48x
EV/Sales	51.05x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.38x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.78x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	143.63x	N/A
Revenue & Growth
Revenue (TTM)	$2M	$41M
Revenue Growth (YoY)	-62.1%	22.0%
Forward Rev Growth	240.0%	-94.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3068.6%	-215.0%
Net Margin (TTM)	-4477.1%	-209.2%
FCF Margin (TTM)	-2865.9%	-193.4%
Net Income (TTM)	$-107M	$-86M
FCF (TTM)	$-68M	$-80M
EPS (TTM)	-$6.05	-$5.05
ROE (TTM)	-11426.0%	-4030.0%
ROA (TTM)	-6857.0%	-5864.0%
ROIC (TTM)	-11426.0%	-4433.7%
Financial Health
Cash	$25M	$72M
Debt	$0	$0
Net Cash/Debt	$25M	$72M
Current Ratio (TTM)	9.55x	8.73x
Quick Ratio (TTM)	9.11x	8.59x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.27	1.20
52W Performance	-77.8%	-82.6%
YTD Performance	26.2%	-88.3%
% from 52W High	-81.8%	-88.5%
% from 52W Low	95.2%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.28x
FCF Yield (TTM)	-46.6%	-55.5%
Earnings Yield (TTM)	-72.8%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,927.9	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View KRRO research	View RNA research

Valuation

P/S Ratio

RNA

3.48x

KRRO

61.51x

EV/FCF

KRRO

-1.78x

RNA

-0.89x

Growth & revenue

Revenue Growth TTM

RNA

22.0%

KRRO

-62.1%

Forward Revenue Growth

KRRO

240.0%

RNA

-94.2%

Profitability & performance

Gross Margin

KRRO

0.0%

RNA

0.0%

ROE

RNA

-4030.0%

KRRO

-11426.0%

FCF Yield %

KRRO

-46.6%

RNA

-55.5%

52-Week Performance

KRRO

-77.8%

RNA

-82.6%

Detailed metrics comparison

KRRO

Korro Bio Inc

RNA

Atrium Therapeutics Inc

Market Cap

KRRO$147M

RNA$144M

Enterprise Value

KRRO$122M

RNA$71M

Price

KRRO$10.16

RNA$8.40

P/E Ratio

KRRON/A

RNAN/A

P/S Ratio

KRRO61.51x

RNA3.48x

EV/Sales

KRRO51.05x

RNA1.73x

EV/EBITDA

KRRO0.00x

RNA0.00x

P/B Ratio

KRRO1.38x

RNA0.63x

P/FCF Ratio

KRRON/A

RNAN/A

EV/FCF

KRRO-1.78x

RNA-0.89x

PEG Ratio

KRRON/A

RNAN/A

Forward P/E (NTM)

KRRON/A

RNAN/A

Forward P/S (NTM)

KRRO143.63x

RNAN/A

Revenue (TTM)

KRRO$2M

RNA$41M

Revenue Growth (YoY)

KRRO-62.1%

RNA22.0%

Forward Rev Growth

KRRO240.0%

RNA-94.2%

Gross Margin (TTM)

KRRO0.0%

RNA0.0%

Operating Margin (TTM)

KRRO0.0%

RNA0.0%

EBITDA Margin (TTM)

KRRO-3068.6%

RNA-215.0%

Net Margin (TTM)

KRRO-4477.1%

RNA-209.2%

FCF Margin (TTM)

KRRO-2865.9%

RNA-193.4%

Net Income (TTM)

KRRO$-107M

RNA$-86M

FCF (TTM)

KRRO$-68M

RNA$-80M

EPS (TTM)

KRRO-$6.05

RNA-$5.05

ROE (TTM)

KRRO-11426.0%

RNA-4030.0%

ROA (TTM)

KRRO-6857.0%

RNA-5864.0%

ROIC (TTM)

KRRO-11426.0%

RNA-4433.7%

Cash

KRRO$25M

RNA$72M

Debt

KRRO$0

RNA$0

Net Cash/Debt

KRRO$25M

RNA$72M

Current Ratio (TTM)

KRRO9.55x

RNA8.73x

Quick Ratio (TTM)

KRRO9.11x

RNA8.59x

Debt/Equity (TTM)

KRRO0.00x

RNA0.00x

Debt/Assets (TTM)

KRRO0.0%

RNA0.0%

Interest Coverage (TTM)

KRRON/A

RNAN/A

Net Debt/EBITDA (TTM)

KRRO0.00x

RNA0.00x

Beta

KRRO3.27

RNA1.20

52W Performance

KRRO-77.8%

RNA-82.6%

YTD Performance

KRRO26.2%

RNA-88.3%

% from 52W High

KRRO-81.8%

RNA-88.5%

% from 52W Low

KRRO95.2%

RNA10.1%

Asset Turnover (TTM)

KRRO0.04x

RNA0.28x

FCF Yield (TTM)

KRRO-46.6%

RNA-55.5%

Earnings Yield (TTM)

KRRO-72.8%

RNA-60.1%

Dividend Yield (TTM)

KRRON/A

RNAN/A

Rule of 40

KRRO-2,927.9

RNA-171.3

EV/GP/RG

KRRON/A

RNAN/A

Ticker research

View KRRO research View RNA research

Metric	KRRO Korro Bio Inc	RNA Atrium Therapeutics Inc
Market & Valuation
Market Cap	$147M	$144M
Enterprise Value	$122M	$71M
Price	$10.16	$8.40
P/E Ratio	N/A	N/A
P/S Ratio	61.51x	3.48x
EV/Sales	51.05x	1.73x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.38x	0.63x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.78x	-0.89x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	143.63x	N/A
Revenue & Growth
Revenue (TTM)	$2M	$41M
Revenue Growth (YoY)	-62.1%	22.0%
Forward Rev Growth	240.0%	-94.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-3068.6%	-215.0%
Net Margin (TTM)	-4477.1%	-209.2%
FCF Margin (TTM)	-2865.9%	-193.4%
Net Income (TTM)	$-107M	$-86M
FCF (TTM)	$-68M	$-80M
EPS (TTM)	-$6.05	-$5.05
ROE (TTM)	-11426.0%	-4030.0%
ROA (TTM)	-6857.0%	-5864.0%
ROIC (TTM)	-11426.0%	-4433.7%
Financial Health
Cash	$25M	$72M
Debt	$0	$0
Net Cash/Debt	$25M	$72M
Current Ratio (TTM)	9.55x	8.73x
Quick Ratio (TTM)	9.11x	8.59x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	3.27	1.20
52W Performance	-77.8%	-82.6%
YTD Performance	26.2%	-88.3%
% from 52W High	-81.8%	-88.5%
% from 52W Low	95.2%	10.1%
Efficiency & Yields
Asset Turnover (TTM)	0.04x	0.28x
FCF Yield (TTM)	-46.6%	-55.5%
Earnings Yield (TTM)	-72.8%	-60.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2,927.9	-171.3
EV/GP/RG	N/A	N/A
Ticker research	View KRRO research	View RNA research